Articles

Chicago, IL—Exemestane (Aromasin) appears to be a good alternative to tamoxifen (Nolvadex) for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial reported at ASCO 2011.

New understanding of the mechanism of cancer as genetic and molecular cancer–causing lesions has enabled the development of targeted therapies that are producing excellent results in early clinical trials.

The Florida Comprehensive Care Network (FCCN), a statewide network of medical and radiation oncologists providing comprehensive, evidence-based care to patients with cancer, has signed an agreement with ITA Partners that allows FCCN to use ITA’s oncology decision-support platform (called eviti) across its network of oncologists.

A new report published in March in the Journal of the National Cancer Institute (2011;103:714-736) shows slow but consistent reductions in some cancer types in men and women between 2003 and 2007, the most recent years for which data are available.

Researchers from Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, identified 2 regulatory molecules that enable a tumor, which originally is usually not deadly, to metastasize.

A survey of 61 patients with cancer suggests that many patients are willing to undergo extra tests to participate in clinical trials that will give them access to experimental cancer treatments that may offer improved outcomes and potentially increased survival options.

A new, ready-to-use (RTU) injectable formulation of the folate analog levoleucovorin (Fusilev; Spectrum Pharmaceuticals) received FDA approval.

Sunitinib (Sutent; Pfizer) is the second new option for the treatment of metastasized or unresectable locally advanced progressive pancreatic neuroendocrine cancerous tumors.